Using Virtual Reality and AI to Treat Psychosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to explore the effectiveness of a novel treatment combining cognitive behavioral therapy-based virtual reality (VR) with advanced artificial intelligence (AI) for patients with psychosis. The study will assess the short- and long-term impacts of the RecoVRy application on psychiatric symptoms, quality of life, and real-world functioning among participants. A total of 150 individuals aged 17 to 65, diagnosed with schizophrenia spectrum psychosis or affective disorders with psychotic symptoms, will be recruited from participating hospital trusts. The trial seeks to address the significant challenges faced by patients, particularly those experiencing anxiety that hinders their daily activities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 17 -65 years of age
* Receiving psychosis treatment at either clinic in the participating hospital trusts
* A clinical diagnosis of schizophrenia spectrum psychosis according to ICD-10 (F20 - F29) or an affective diagnosis with psychotic symptoms (F31.2, F31.5, F32.3, F33.3)
* Self-reported difficulties going outside or taking part in everyday activities
* Willing and able to provide written informed consent for participation in the study

Exclusion Criteria:

* Photosensitive epilepsy
* Substantial visual, auditory, or balance impairments
* Insufficient comprehension of Norwegian
* Currently receiving treatment in a forensic setting or Psychiatric Intensive Care Unit
* Primary diagnosis of alcohol or substance use disorder or personality disorder; organic syndrome
* Clinically significant learning disability

Where it's running

• Oslo University Hospital
  Oslo, Norway, Norway Recruiting
• Oslo University Hospital
  Nydalen, Norway Active not recruiting

Study contacts

• Principal investigator: Jan Ivar Røssberg, PhD — Universitetet i Oslo/Oslo universitetssykehus
• Study coordinator: Jan Ivar Røssberg, Professor
• Email: j.i.rossberg@medisin.uio.no
• Phone: +47 47876866

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Examining the effects of combined therapy for schizophrenia

  This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.

  Recruiting at 2 sites University of Toronto · Scarborough Village, Ontario and 1 other locations · NCT05731414

• State Representation in Early Psychosis 2

  This observational study tests how people with early psychosis and healthy individuals use state information during tasks and how brain activity supports it.

  Recruiting at 2 sites University of Minnesota · Minneapolis, Minnesota and 1 other locations · NCT07834203

• Recovery-oriented suicide prevention for young people at clinical high risk for psychosis

  This program tests a peer-supported, clinician-led suicide prevention group for young people at clinical high risk for psychosis to see if it helps reduce suicidal thoughts and support recovery.

  Recruiting at 2 sites University of California, San Diego · Los Angeles, California and 1 other locations · NCT07756567

• Combined brain stimulation and yoga for improving cognition in psychosis

  This study tests whether active brain stimulation plus yoga can improve thinking skills and daily function in adults with psychosis.

  Recruiting The Hong Kong Polytechnic University · Hung Hom, Kowloon · NCT07747181

• See if an early-detection program reduces time to treatment for first-episode psychosis

  We test whether a large, region-wide early-detection program can shorten the time from first psychotic symptoms to treatment and help people function better later.

  Recruiting at 2 sites Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Copenhagen, Denmark and 1 other locations · NCT07716969

• Cerebellar imaging markers to predict antipsychotic response in first-episode psychosis

  This will test whether cerebellar brain scans can predict how people with first-episode psychosis respond to 12 weeks of treatment with risperidone or aripiprazole.

  Recruiting Phase 4 Northwell Health · Glen Oaks, New York · NCT07483294

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.